Multiple factors such as RA disease duration, autoantibody [rheumatoid factor (RF) or anti cyclic citrullinated peptide antibody (ACPA)] status, or smoking status can influence treatment response to different medications in patients with RA. This evidence concerns the gene PRTN3 and rheumatoid arthritis.